- From: 'Christopher A Domarew' <chris@domarew.com>
- Date: Tue, 15 Feb 2011 11:36:41 +0000
- To: 'Eric Prud'hommeaux' <eric@w3.org>, public-semweb-lifesci@w3.org
- Cc: 'Helena Deus' <helenadeus@gmail.com>
- Message-Id: <6d91d572baa79fc44f112ff44e1d8330a7792719@webmail.theside.co.uk>
Eric, Here is one I found : I can get you the full text if you need it. Searching for more. does this help? C A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. AU Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, SO Neurology. 2009;73(24):2061-70. BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. METHODS: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 10, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline. RESULTS: No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p Links: ------ [1] http://www.w3.org/wiki/HCLSIG/PharmaOntology/Queries#Q6._Are_there_any_AD_patients_without_the_APOE4_allele_as_these_would_be_good_candidates_for_the_clinical_trial_involving_Bapineuzumab.3F
Received on Tuesday, 15 February 2011 11:37:14 UTC